Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Date:9/11/2012

CRANBURY, N.J., Sept. 11, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012. 

Fiscal Year and Recent Highlights

  • Bremelanotide development for Female Sexual Dysfunction (FSD):
  • Palatin completed patient treatment in its Phase 2B clinical trial in premenopausal women with FSD
  • Primary data analysis and announcement of top-line results anticipated in first-half of fourth quarter of calendar year 2012
  • Obesity Collaboration with AstraZeneca:
  • Multiple classes of collaboration compounds have advanced to various stages of development. Though collaboration partner AstraZeneca has decided to discontinue further development of AZD2820, the only compound in clinical trials, AstraZeneca remains committed to this collaboration program and to the continued advancement of collaboration compounds for treatment of obesity.
  • Intellectual property developments:
  • Two additional United States patents have issued in the melanocortin field
  • Palatin has advanced its bremelanotide, PL-3994, and new melanocortin peptide patent applications in countries outside the United States
  • Equity financing:
  • On July 3, 2012, Palatin closed on a $35.0 million private placement.  The offering consisted of the sale of 3,873,000 shares of common stock, Series A 2012 warrants to purchase 31,988,151 shares of common stock, and Series B 2012 warrants to purchase 35,488,380 shares of common stock.
  • Net proceeds to Palatin after deducting offering expenses were $34.5 million 
  • Fourth Quarter and Fiscal Year End 2012 ResultsPalatin reported a net loss of $5.3 million, or $(0.14) per basic and diluted share
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
    2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the Company and ... 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy ... Santa Ana division (the "Bankruptcy Court") on ... to be jointly administered. The Company will evaluate ... for all or substantially all of its assets to a ...
    (Date:3/3/2015)... Cambridge Semantics, the leading provider of smart ... that it has been named to KMWorld’s 2015 list ... , To create the list each year, KMWorld ... integrators who identify organizations dedicated to the true value ... the right people at the right time. , ...
    (Date:3/3/2015)...  Johnson & Johnson Innovation LLC today announced the ... (JLABS @SSF), a 30,000-square foot incubator located at ... Calif. The Johnson & Johnson Innovation, JLABS ... across the healthcare spectrum including biotech, pharmaceutical, medical device, ... resident startups have been selected, including the winners of ...
    (Date:3/3/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announced it has initiated commissioning activities for its 30,000 ... Sarnia, Ontario , Canada.  Commissioning ... with the facility being in commercial operation in Q3 ... two months and it is carrying out commissioning and ...
    Breaking Biology Technology:AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4Cambridge Semantics Named to KMWorld’s 2015 ‘100 Companies That Matter in Knowledge Management’ 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
    ... GmbH and BASF developed pro-t-action(TM) product based on probiotic ... oral careFull research studies introduced at International Association of ... FL , April 1-4 LUDWIGSHAFEN, Germany and ... remedy a main cause of tooth decay affecting an ...
    ... Board: SNKTY), a Life Sciences company engaged in the ... today announced plans for the creation of a new communication ... updated on key events. Bi-weekly updates will be recorded on ... and running in early May. In addition, callers will be ...
    ... Neuroscience paper describes role of Zinc in developing Alzheimer,s ... PRAN ) today announced that an independent ... California, Irvine , validates Prana,s fundamental drug strategy for ... and brain metals, such as zinc, that damages synapses ...
    Cached Biology Technology:BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 2BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 3BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 4BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 5Senetek PLC Announces New Investor Communication Hotline 2Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients. 2Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients. 3Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients. 4
    (Date:2/5/2015)... , Jan. 28, 2015 Research and Markets ... addition of the "Global Biometrics Market (2014-2020): ... and Countries " report to their offering. ... Asia-Pacific is anticipated to overtake ... owing to increasing government spending towards IT security, ...
    (Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
    (Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
    Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
    ... This press release is available in Spanish . ... real headache. U.S. Department of Agriculture (USDA) scientists have identified ... and offer a potential bio-based approach to controlling them. Other ... termite, a nonnative species from Asia, feeds on cellulose from ...
    ... shown that 30 minutes of daily training provide an equally effective ... have just been published in the American Journal of Physiology ... thirteen weeks, a research team at the Faculty of Medical and ... in their efforts to get into better shape. Half of the ...
    ... BOSTON, Aug. 22, 2012 Evermedia Group, Inc. (OTC: EVRM) ... 2012 revenue of $703,620, an increase of more than 375% ... all revenue generated in fiscal year 2011 as represented by ... increase in revenue is largely attributable to revenue generated by ...
    Cached Biology News:Nematodes with pest-fighting potential identified 230 minutes of daily exercise does the trick 2Evermedia Group Announces 375% Increase in Revenue for Second Quarter 2012 2Evermedia Group Announces 375% Increase in Revenue for Second Quarter 2012 3
    Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
    Laminin beta-1/gamma-1 (612C10)...
    ... choice of Printing Surface (3 glass slides coated with ... 1 silicon wafer coated with 1000 Angstroms of Gold ... PDMS Stamps (3 PDMS micropatterned stamps with series of ... 10 mm or 200 um x 10 mm lines, ...
    X box-binding protein 1...
    Biology Products: